Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1655-1663

  Mirochnik, Yelena ^a   Aurora, Arin ^a,d   Schulze Hoepfner, Frank T ^a,c   Deabes, Ahmed ^a   Shifrin, Victor ^e   Beckmann, Richard ^b   Polsky, Charles ^b   Volpert, Olga V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Arbus Pharmaceuticals   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e International Consulting Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPITOPE; FAS LIGAND; PIGMENT EPITHELIAL DERIVED FACTOR; PROTEIN P14; PROTEIN P18; PROTEIN P23; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELLS, CULTURED; CHEMOTAXIS; CORNEAL NEOVASCULARIZATION; ENDOTHELIUM, VASCULAR; EYE PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; SERPINS; UMBILICAL VEINS;

EID: 63449111231     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2113     Document Type: Article

References (33)

1. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339-47.
2. Desai AA, StadlerWM. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep 2005;7:116-22.
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391 -400.
4. Mariani SM. Anti-angiogenesis: the challenges ahead. Med Gen Med 2003;5:22.
5. Sund M, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005;102:2934-9.
6. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res1996;69:135-74.
7. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112:496-507.
8. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
9. Ek ET, Dass CR, Choong PF. PEDF:a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006;12:497-502.
10. Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epithelium-derived factor asa multifunctional antitumor factor. J Mol Med 2007;85:15-22.
11. Becerra SP. Focuson molecules: pigment epithelium-derived factor (PEDF). Exp Eye Res 2006;82: 739-40.
12. Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Front Biosci 2005;10: 2131 -49.
13. Filleur S, et al. Two functional epitopesof pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005;65:5144-52.
14. Becerra SP. Structure-function studies on PEDF. A noninhibitory serpin with neurotrophic activity. Adv Exp Med Biol 1997;425:223-37.
15. Smith ND, Schulze-Hoepfner FT, Veliceasa D, et al. Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. J Urol 2008;179: 2427-34.
16. Notari L, et al. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 2006;281:38022-37.
17. Apte RS, Barreiro RA, Duh E, Volpert O, Ferguson TA. Stimulation of neovascularization by the antiangiogenic factor PEDF. Invest Ophthalmol Vis Sci 2004;45:4491-7.
18. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004; 14:287-300.
19. Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des2007;13:2074-86.
20. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 2006;281: 3604-13.
21. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U SA1990;87:6624-8.
22. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, DAmato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996;37:1625-32.
23. Passaniti A, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67: 519-28.
24. 24.Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003;8: 72-9.
25. Polverini PJ, Bouck NP, Rastinejad F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol 1991;198:440-50.
26. Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV. Nuclear factor of activated T cells balancesangiogenesis activation and inhibition. J Exp Med 2004;199:1513-22.
27. Volpert OV, Zaichuk T, Zhou W, et al. Inducerstimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8: 349-57.
28. Ek ET, Dass CR, Contreras KG, Choong PF. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis 2007; 24:93-106.
29. Doll JA, et al. Pigment epithelium-derived factor regulatesthe vasculature and massof the prostate and pancreas. Nat Med 2003;9:774-80.
30. Garcia M, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activitiesof pigment epithelium-derived factor. Cancer Res2004; 64:5632-42.
31. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 2007;14:616-26.
32. Guan M, Pang CP, Yam HF, Cheung KF, Liu WW, Lu Y Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004;11:325-32.
33. Ek ET, Dass CR, Contreras KG, Choong PF. PEDF- derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res2007;25:1671 -80.